Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Create Medic Co., Ltd. (5187.T)
Yokohama, JP
Create Medic Co., Ltd. engages in the research, manufacturing, and sale of medical appliances in Japan, China, Vietnam, and internationally. The company offers urology products, including all silicone foley, antibacterial foley, hematuria, tieman, suprapubic, and nephrostomy balloon catheters, as well as self-catheterization set, all silicone self-catheter for replacement, pure-cath, nephrostomy kit, cystostomy set, and all silicone malecot catheter; and gastroenterology products, such as all silicone ileus, stomach, and sengstaken blakemore tubes, as well as transanal ileus decompression tube set. It also provides PEG products comprising PEG kit pull-method, with loop fixture, and bumper type, as well as CLINY introducer PEG kit, loop fixture II, all silicone gastrostomy balloon catheter for replacement, balloon button set, facil button for replacement, gastrostomy replacement catheter set, all silicone PEG J catheter, and transgastric jejunal balloon tube and guidewire set; surgery products, which include PTC drainage tube, PTCD kit, cholangio-entero tube, and internal external drainage catheter for PTCD; all silicone endotracheal and tracheostomy tubes and micro catheter; and OEM products. The company was formerly known as NASK Co., Ltd. and changed its name to Create Medic Co., Ltd. in July 1977. Create Medic Co., Ltd. was incorporated in 1974 and is headquartered in Yokohama, Japan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.13% | -5.25% | -5.49% | -1.56% | +11.25% | +10.07% | +16.74% | +25.08% | +13.36% | +33.92% | +132.04% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Specialties: +8.3%+4.5% Q1'26: +4.5% (vs Q1'25)
-
EPS growth Medical - Specialties: +10.1%-15.3% Q1'26: -32.0% (vs Q1'25)
-
FCF margin FCF growth · Medical - Specialties: +51.3%-0.3% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Medical - Specialties: +12.6%+7.4% Q1'26: +4.2% (vs Q1'25)
-
ROIC Medical - Specialties: +6.6%+6.0% Q1'26: +4.4% (vs Q1'25)
-
Share dilution Medical - Specialties: 0.0%+0.3% Q1'26: +7.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Specialties: -0.39×0.48× ★ Q1'26: 0.64× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | A- | 4/5 | 3/5 | 3/5 | 4/5 | 3/5 | 3/5 | 5/5 |
| 2026-05-01 | A- | 4/5 | 3/5 | 3/5 | 4/5 | 3/5 | 3/5 | 5/5 |
| 2026-04-30 | A- | 4/5 | 3/5 | 3/5 | 4/5 | 3/5 | 3/5 | 5/5 |
| 2026-04-28 | B+ | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-27 | B+ | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-24 | B+ | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-23 | A- | 4/5 | 3/5 | 2/5 | 5/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-22 | A- | 4/5 | 3/5 | 2/5 | 5/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-21 | A- | 4/5 | 3/5 | 2/5 | 5/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-20 | A- | 4/5 | 3/5 | 2/5 | 5/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-17 | A- | 4/5 | 4/5 | 2/5 | 5/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-16 | A- | 4/5 | 4/5 | 2/5 | 5/5 | 2/5 | 3/5 | 5/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Akiya Ueno | Accounting Department Manager | — | — |
| Osamu Imazawa | Chief Executive Officer, President & Representative Director | — | — |
| Yozo Akaoka | Senior MD & Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 5187.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
